Trastuzumab Recruiting Phase 2 Trials for Estrogen Receptor Positive / Stage IIB Breast Cancer / Triple-Negative Breast Cancer (TNBC) / Stage II Breast Cancer / Her2-Positive Breast Cancer / Stage III Breast Cancer / Estrogen Receptor Negative / Stage IIA Breast Cancer / Progesterone Receptor-negative Breast Cancer / Estrogen Receptor-negative Breast Cancer / Progesterone Receptor-positive Breast Cancer / Invasive Breast Carcinoma / Stage IA Breast Cancer / HER2/Neu Positive / HER2-Negative Breast Cancer / Progesterone Receptor Positive / HER2/Neu Negative / Progesterone Receptor Negative / Stage IIIC Breast Cancer / Stage IIIB Breast Cancer / Triple-Negative Breast Carcinoma / Stage IIIA Breast Cancer / Estrogen Receptor-Positive Breast Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03094052Diarrhea Prophylaxis in Patients With HER2+ Breast Cancer Treated With Trastuzumab and Neratinib, Followed by Neratinib Monotherapy
NCT01750073Paclitaxel and Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Patients With Previously Untreated Breast Cancer
NCT03125928Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer